Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.
Inflammatory bowel diseases (IBDs) such as Crohn's disease are highly debilitating. There are inconsistencies in response to and side effects in the current conventional medications, failures in adequate drug delivery, and the lack of therapeutics to offer complete remission in the presently available treatments of IBD. This suggests the need to explore beyond the horizons of conventional approaches in IBD therapeutics. This review examines the arena of the evolving IBD nanomedicine, studied so far in animal and in vitro models, before comprehensive clinical testing in humans. The investigations carried out so far in IBD models have provided substantial evidence of the nanotherapeutic approach as having the potential to overcome some of the current drawbacks to conventional IBD therapy. We analyze the pros and cons of nanotechnology in IBD therapies studied in different models, aimed at different targets and mechanisms of IBD pathogenesis, in an attempt to predict its possible impact in humans.
Madharasi V A
MV
Pichai
Lynnette R
LR
Ferguson
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D019938:Cyclin D1 / Q000235:genetics; D020868:Gene Silencing; D006801:Humans; D020782:Matrix Metalloproteinases / Q000235:genetics; D019804:Mesalamine / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D036103:Nanotechnology; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
D000894:Anti-Inflammatory Agents, Non-Steroidal; D014409:Tumor Necrosis Factor-alpha; D019938:Cyclin D1; D019804:Mesalamine; D020782:Matrix Metalloproteinases